Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation

Abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.

1 . A method of reducing IL-17A-induced or IL-17F-induced inflammation comprising administering to a mammal with inflammation a soluble receptor comprising a ZcytoR14 subunit and an IL-17RA subunit in an amount sufficient to reduce inflammation.  
     
     
         2 . A method of reducing IL-17A-induced and IL-17F-induced inflammation comprising administering to a mammal with inflammation a soluble receptor comprising a ZcytoR14 subunit and an IL-17RA subunit in an amount sufficient to reduce inflammation.  
     
     
         3 . A method of treating a mammal afflicted with an inflammatory disease in which IL-17A or IL-17F plays a role, comprising: administering a soluble receptor comprising a ZcytoR14 subunit and an IL-17RA subunit to the mammal such that the inflammation is reduced, wherein the inflammatory activity of either IL-17A (SEQ ID NO:14) or IL-17F (SEQ ID NO:16) is reduced.  
     
     
         4 . The method of  claim 3 , wherein the disease is asthma.  
     
     
         5 . The method of  claim 3 , wherein the disease is a chronic inflammatory disease.  
     
     
         6 . The method of  claim 5 , wherein the disease is a chronic inflammatory disease comprising inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, atopic dermatitis, or psoriasis.  
     
     
         7 . The method of  claim 3 , wherein the disease is an acute inflammatory disease.  
     
     
         8 . The method of  claim 7 , wherein the disease is an acute inflammatory disease comprising endotoxemia, septicemia, toxic shock syndrome or infectious disease.  
     
     
         9 . A method of treating a mammal afflicted with an inflammatory disease in which IL-17A and IL-17F plays a role, comprising: administering a soluble receptor comprising a ZcytoR14 subunit and an IL-17RA subunit to the mammal such that the inflammation is reduced, wherein the inflammatory activity of both IL-17A (SEQ ID NO:14) and IL-17F (SEQ ID NO:16) is reduced.  
     
     
         10 . The method of  claim 9 , wherein the disease is asthma.  
     
     
         11 . The method of  claim 9 , wherein the disease is a chronic inflammatory disease.  
     
     
         12 . The method of  claim 11 , wherein the disease is a chronic inflammatory disease comprising inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, atopic dermatitis, or psoriasis.  
     
     
         13 . The method of  claim 9 , wherein the disease is an acute inflammatory disease.  
     
     
         14 . The method of  claim 13 , wherein the disease is an acute inflammatory disease comprising endotoxemia, septicemia, toxic shock syndrome or infectious disease.  
     
     
         15 . A method of treating a pathological condition in a subject associated with IL-17A or IL-17F activity comprising administering an effective amount of a soluble receptor comprising a ZcytoR14 subunit and an IL-17RA subunit, thereby treating said pathological condition.  
     
     
         16 . The method of  claim 15 , wherein said pathological condition is asthma.  
     
     
         17 . The method of  claim 15 , wherein said pathological condition is a chronic inflammatory condition.  
     
     
         18 . The method of  claim 17 , wherein said chronic inflammatory condition comprising inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, atopic dermatitis, or psoriasis.  
     
     
         19 . The method of  claim 15 , wherein said pathological condition is an acute inflammatory condition.  
     
     
         20 . The method of  claim 19 , wherein said acute inflammatory condition comprises endotoxemia, septicemia, toxic shock syndrome, or infectious disease.  
     
     
         21 . A method of treating a pathological condition in a subject associated with IL-17A and IL-17F activity comprising administering an effective amount of a soluble receptor comprising a ZcytoR14 subunit and an IL-17RA subunit, thereby treating said pathological condition.  
     
     
         22 . The method of  claim 21 , wherein said pathological condition is asthma.  
     
     
         23 . The method of  claim 21 , wherein said pathological condition is a chronic inflammatory condition.  
     
     
         24 . The method of  claim 23 , wherein said chronic inflammatory condition comprising inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, atopic dermatitis, or psoriasis.  
     
     
         25 . The method of  claim 21 , wherein said pathological condition is an acute inflammatory condition.  
     
     
         26 . The method of  claim 25 , wherein said acute inflammatory condition comprises endotoxemia, septicemia, toxic shock syndrome, or infectious disease.